Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.56 |
| ▸ | RAB9A | P51151 | 5/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.56 |
| ▸ | NPC1 | O15118 | 4/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | LMNA | P02545 | 3/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.53 |
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 6/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.49 |
| ▸ | P2RX1 | P51575 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27708003 | 0.83 | MAPT (0.53) | MAPTRAB9ASMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL28770492 | 0.83 | MAPT (0.53) | MAPTRAB9ASMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL1408451 | 0.82 | MEN1 (0.62) | MAPTRAB9ASMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL1409161 | 0.82 | KDR (0.47) | TRPV1P2RX1ACKR3 | |
| SCHEMBL1449042 | 0.77 | KMT2A (0.55) | MAPTRAB9ASMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL29877893 | 0.77 | MAPT (0.57) | MAPTRAB9ASMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL29878811 | 0.77 | MAPT (0.60) | MAPTRAB9ASMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL7820503 | 0.77 | CYP1A2 (0.68) | MAPTRAB9ASMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL29877516 | 0.76 | MAPT (0.53) | MAPTRAB9ASMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL100511 | 0.76 | RAB9A (0.56) | MAPTRAB9ASMN1; SMN2NPC1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1786799-A1 | NOVEL PHENYLAMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF BCR-ABL KINASE | Natco Pharma Limited (IN) | 2007-05-23 | — | — | EP | claimed |
| WO-2006027795-A1 | NOVEL PHENYLAMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF BCR-ABL KINASE | NATCO PHARMA LIMITED (IN) | 2006-03-16 | — | — | WO | claimed |
| EP-2295424-B1 | Processes for the preparation of novel phenylaminopyrimidine derivatives as inhibitors of BCR-ABL kinase | NATCO PHARMA LTD (IN) | 2015-10-14 | — | — | EP | disclosed |
| EP-1786799-B1 | NOVEL PHENYLAMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF BCR-ABL KINASE | NATCO PHARMA LTD (IN) | 2012-07-04 | — | — | EP | disclosed |
| US-8183253-B2 | Condensing (3-trifluoromethylsulfonyl) benzoyl chloride and 4-methyl-2-nitro-aniline; reducing nitro group with stannous chloride; condensing amino group with cyanamide; cyclocondensing guanidine group with 3-dimethylamino-1-pyridin-3-yl-propenone; antiproliferative agents; chronic myeloid leukemia | NATCO PHARMA LIMITED (IN) | 2012-05-22 | — | — | US | disclosed |
| US-7910598-B2 | Condensing (3-trifluoromethylsulfonyl) benzoyl chloride and 4-methyl-2-nitro-aniline; reducing nitro group with stannous chloride; condensing amino group with cyanamide; cyclocondensing guanidine group with 3-dimethylamino-1-pyridin-3-yl-propenone; antiproliferative agents | NATCO PHARMA LIMITED (IN) | 2011-03-22 | — | — | US | disclosed |
| EP-2295424-A1 | Processes for the preparation of novel phenylaminopyrimidine derivatives as inhibitors of BCR-ABL kinase | Natco Pharma Limited (IN) | 2011-03-16 | — | — | EP | disclosed |
| US-20080306100-A1 | PHENYLAMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF BCR-ABL KINASE | NATCO PHARMA LIMITED (IN) | 2008-12-11 | — | — | US | disclosed |
| CN-101068805-A | Novel phenylaminopyrimidine derivatives as inhibitors of BCR-ABL kinase | NATCO PHARMA LTD (IN) | 2007-11-07 | — | — | CN | disclosed |
| US-20070232633-A1 | Novel phenylaminopyrimidine derivatives as inhibitors of BCR-ABL kinase | NATCO PHARMA LIMITED (IN) | 2007-10-04 | — | — | US | disclosed |
| EP-1786799-A1 | NOVEL PHENYLAMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF BCR-ABL KINASE | Natco Pharma Limited (IN) | 2007-05-23 | — | — | EP | disclosed |
| WO-2006027795-A1 | NOVEL PHENYLAMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF BCR-ABL KINASE | NATCO PHARMA LIMITED (IN) | 2006-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232633-A1 | Novel phenylaminopyrimidine derivatives as inhibitors of BCR-ABL kinase | ABL1, ABL2, BCR | MAPT 4071/4885RAB9A 2761/4885SMN1; SMN2 3960/4885 |
| US-20080306100-A1 | PHENYLAMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF BCR-ABL KINASE | ABL1, ABL2, BCR | MAPT 3099/4885RAB9A 2568/4885SMN1; SMN2 2748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.